NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT05974410 2025-10-02Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAVM Biotechnology IncAvailable
NCT04681248 2025-08-03Expanded Access Use of DKN-01 for the Treatment of Advanced Solid TumorsLeap Therapeutics, Inc.No longer available
NCT02065765 2025-01-09International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric CancerEli Lilly and CompanyApproved for marketing
NCT02209441 2014-08-06Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric CancerChineseAMSAvailable